Pulse.

a daily field guide to health research that matters

◆ Console

‹ Tue · 10 Nov 2026
Standard addition

Validation of a ctDNA-Based comprehensive genomic profiling panel (IST80 Plus) for advanced non-small cell lung cancer.

Blood tests can now reliably detect cancer-related DNA patterns with high accuracy, offering a non-invasive way to monitor disease.

We evaluated the analytical and clinical performance of Illumina Solid Tumor Panel 80 (IST80 Plus), a focused hybrid-capture next-generation sequencing assay for plasma genomic profiling. IST80 Plus showed high sensitivity and quantitative accuracy for small variants and reliable fusion detection in ctDNA.

What the study was

Study design
Validation study
Population
Validation included Seraseq-ctDNA reference materials at 2.5% and 0.5% allele frequencies, six external quality-assessment samples, supernatants from three fusion-positive cell lines, and eighteen plasma samples from patients with previously characterized NSCLC alterations.
Category
Early Detection
Maturity
Validated
Journal
The journal of liquid biopsy

Why it surfaced

Validation study assessed from PubMed metadata and abstract text; conservatively scored 8/10 under the v1.3 rubric.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.